Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies

About the trial

Sponsor

Regeneron Pharmaceuticals

Tested

Cemiplimab (drug), Ipilimumab (drug), Platinum-doublet chemotherapy (drug), Gemcitabine (drug), Pemetrexed (drug), Paclitaxel (drug), Fianlimab (drug)

Dates

Started 2017-06-21; completion 2027-09-30

Results posted

Not yet

Part 2 Cohorts A and C This study is being conducted to test the safety and pharmacokinetics of cemiplimab in patients with lung cancer. The study is also being conducted to test if cemiplimab, alone or in combination, can reduce the size of your tumor by helping the immune system destroy the tumor. Part 2 Cohorts D and E This study is being conducted to test the safety and pharmacokinetics of fianlimab and cemiplimab in patients with lung cancer. The study is also being conducted to test if fianlimab and cemiplimab, with or without chemotherapy, can reduce the size of your tumor by helping the immune system destroy the tumor.

From ClinicalTrials.gov, last updated 2026-02-12. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Regeneron Pharmaceuticals, Inc. reported $38,770 in research payments for this study in 2025 (64 payments).

Products named: Libtayo

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.